Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution
Thyroid® · 2024-04 · 34 (4) · 460-466
DOI: 10.1089/thy.2023.0664 ↗At a glance
Journal article in Thyroid®, published online on 2024-04-04. Written by Mason D Stillman and 7 co-authors. Institution: Division of GI/Endocrine Surgery, Columbia University Irving Medical Center, New York, New York, USA. Major MEDLINE topics: Thyroid Nodule, Thyroid Neoplasms. Cited 7 times so far (Crossref); 21 references.
Abstract (original language)
Background
Molecular testing (MT) has become standard practice to more accurately rule out malignancy in indeterminate Bethesda III (BIII) thyroid lesions. We sought to assess the adoption of this technology and its impact on cytology reporting, malignancy yield, and rates of surgery across community and academic sites affiliated with a tertiary medical center.
Methods
We performed a retrospective cross-sectional study including all fine-needle aspirations (FNAs) analyzed at our institution from 2017 to 2021. We analyzed trends in MT utilization by platform and by community or academic site. We compared BIII call rates, MT utilization rates, rates of subsequent surgery, and malignancy yield on final pathology before and after MT became readily available using chi-square analysis and linear regression.
Results
A total of 8960 FNAs were analyzed at our institution from 2017 to 2021. There was broad adoption of MT across both community and academic sites. There was a significant increase in both the BIII rate and the utilization of MT between the pre- and post-MT periods ( p < 0.001 and p < 0.001). There was no significant change in the the malignancy yield on final pathology (57.1% vs. 50.0%, p = 0.347), while the positive predictive value of MT decreased from 85% to 50% ( p = 0.008 [confidence interval 9.5–52.5% decrease]).
Conclusions
The use of MT increased across the institution over the study period, with the largest increase seen after a dedicated pass for MT was routinely collected. This increased availability of MT may have led to an unintended increase in the rates of BIII lesions, MT utilization, and surgery for benign nodules. Physicians who use MT should be aware of potential consequences of its adoption to appropriately counsel patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of GI/Endocrine Surgery, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
ORCID profiles: Mason D Stillman, Eric J Kuo, Jennifer H Kuo
Cite
APA
Stillman, M. D., Kuo, E. J., Liou, R., Almuqate, A., Virk, R., Lee, J. A., Kuo, J. H., & McManus, C. M. (2024). Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution. Thyroid®, 34(4), 460-466. https://doi.org/10.1089/thy.2023.0664
Vancouver
Stillman MD, Kuo EJ, Liou R, Almuqate A, Virk R, Lee JA, et al. Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution. Thyroid®. 2024;34(4):460-466. doi:10.1089/thy.2023.0664
BibTeX
@article{Stillman2024,
author = {Stillman, Mason D and Kuo, Eric J and Liou, Rachel and Almuqate, Abdullah and Virk, Renu and Lee, James A and Kuo, Jennifer H and McManus, Catherine M},
title = {Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution},
journal = {Thyroid®},
year = {2024},
volume = {34},
number = {4},
pages = {460--466},
doi = {10.1089/thy.2023.0664}
}
EUVIMED